Atrium Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNA research report →
Range $25 – $25
Price Chart
About the company
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy.
- CEO
- Kathleen Gallagher
- IPO
- 2026
- Employees
- 511
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on RNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $234.52M
- P/E
- -3.56
- PEG
- -0.04
- P/S
- 9.98
- P/B
- 1.09
- EV/EBITDA
- -1.89
- Div Yield
- 0.00%
- Gross Margin
- 97.90%
- Op Margin
- -374.21%
- Net Margin
- -361.26%
- ROE
- -39.08%
- ROIC
- -35.08%
Latest fiscal year · YoY change
- Revenue
- $18.62M+0.0%
- Gross Profit
- $18.62M+0.0%
- Op Income
- $-76,814,000
- Net Income
- $-76,684,000+0.0%
- EPS
- $-4.48+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $16.77
- 52W Low
- $11.13
- 50D MA
- $12.41
- 200D MA
- $13.03
- Beta
- 0.37
- RSI (14)
- 71
- Avg Volume
- 194.21K
No earnings-call transcripts are available for RNA yet.
- Free Float
- 91.9%
- Shares Outstanding
- 17.11M
- Float Shares
- 15.72M
of shares held by institutions
167 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 13.65M | ▲ 429.49K |
| Ubs Oconnor LLC | 3.72M | ▲ 3.72M |
| Sessa Capital Im, L.P. | 1.50M | ▲ 948.61K |
| Price T Rowe Associates Inc | 1.47M | ▼ 80.23K |
| Blackrock, Inc. | 1.45M | ▲ 242.19K |
| Kryger Capital Ltd | 1.05M | ▲ 1.05M |
| Vanguard Capital Management LLC | 730.83K | ▲ 103.96K |
| Crcm LP | 641.54K | ▲ 641.54K |
| Tig Advisors, LLC | 561.53K | ▼ 46.02K |
| Geode Capital Management, LLC | 386.93K | ▲ 67.10K |
| Two Sigma Investments, LP | 345.48K | ▲ 166.92K |
| Goldman Sachs Group Inc | 310.34K | ▼ 39.61K |
Held by 123 ETFs
Biggest fund positions in RNA by dollar value.
Our RNA coverage
Recent articles, reports, and earnings notes.
No research on RNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNA report →Atrium Therapeutics Reports Second Quarter 2026 Financial Results
prnewswire.com · Aug 13
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
prnewswire.com · Aug 13
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
247wallst.com · Aug 6
Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average – Here’s Why
defenseworld.net · Jul 22
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Jul 20
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
prnewswire.com · Jul 14
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Jun 23
Atrium Therapeutics Reports First Quarter 2026 Financial Results
prnewswire.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.